Alle Storys
Folgen
Keine Story von AmVac AG mehr verpassen.

AmVac AG

AmVac AG registers progress with the RSV vaccine

Zug (ots)

The Swiss AmVac AG, a biopharmaceutical company
located in Zug, has made significant advances in the manufacture and 
production of its vaccine candidate against RSV over the last few 
months. This vaccine candidate is based on the new Sendai vector 
technology for which Max-Planck-Innovations GmbH has acquired the 
exclusive licence. This technology, which has been developed by Prof.
Wolfgang Neubert's group at the Max Planck Institute of Biochemistry,
can be used for many indications. The initial aim is to offer 
protection against the respiratory syncytial virus (RSV) with a 
vaccine produced on this basis. RSV is a viral pathogen that causes 
severe airway diseases that are characterised by loss of function of 
the mucous membranes. This leads to reduced oxygen uptake and very 
distressing breathlessness. Young children, the elderly, and 
individuals with a weakened immune system are particularly affected 
by this flu-like viral disease. Following the successful technology 
transfer from the Max-Planck-Institute with tremendous support from 
Prof. Wolfgang Neubert, and setting up and training the AmVac 
Research GmbH team, major advances have already been made in the 
manufacture and production of the RSC vaccine candidate. Therefore, 
AmVac Research GmbH is confident that the proof of principle results 
from animal models will already become available this year. This 
would be a major step forward towards the intended aim of using the 
vaccine for humans.
Sendai vector platform technology is an innovative vaccine 
platform for the development of a novel generation of live vaccines. 
It has been developed at the Max Planck Institute of Biochemistry in 
Munich under the leadership of Prof. Dr Wolfgang Neubert. 
Furthermore, AmVac AG is also in possession of the adjuvant family 
Malp 2, licensed from the Helmholtz-Institute in Hanover. Both 
technologies are now to be advanced and optimised together with the 
scientific developers of the two technologies, Prof. Dr Wolfgang 
Neubert and Prof. Dr Carlos Guzman, with the support of Prof. Dr 
Reinhard Glück, President of the Advisory Board and the Swiss Biotech
Association. This concentration of the platform technologies allows 
for significant costs savings in scientific staffing levels.
AmVac AG
AmVac AG is a biopharmaceutical company situated in Switzerland. 
The company focuses on the vaccine market with its above-average 
growth figures. There are two therapeutic vaccines in the pipeline, 
which are soon to be launched in the fields of gynaecology and 
urology. Further innovative vaccines and technologies are at the 
development stage. The renowned market research company Frost & 
Sullivan awarded AmVac AG the coveted prize "Enabling Technology of 
the Year Award" in 2007.

Contact:

Ariane Meynert, Head of PR/IR
Tel.: +41/41/725'32'34
Mobile: +41/79/793'34'19
E-Mail: meynert@amvac.ch

Weitere Storys: AmVac AG
Weitere Storys: AmVac AG
  • 03.12.2009 – 09:54

    V+ invests in AmVac AG

    Zug (ots) - The Swiss biopharmaceuticals company AmVac AG in Zug has joined forces with the long-term strategic investor V+ GmbH & Co Fonds 2 KG. The private equity company based in Dresden has invested CHF 1,500,000 in AmVac AG since the first half of 2009. Last week V+ GmbH & Co Fonds 2 KG announced their intention of acquiring further shares in AmVac AG to the sum of CHF 3,000,000.00. Michael Vogel, spokesman of the investment board: "We agree with boosting ...

  • 14.07.2008 – 14:25

    AmVac AG Expands Its Advisory Board with Hartmut Retzlaff, CEO of STADA Arzneimittel AG

    Zug (ots) - The Swiss company AmVac AG, a biopharmaceutical company based in Zug, has announced the expansion of its Advisory Board. With the acquisition of Hartmut Retzlaff, CEO of STADA Arzneimittel AG, AmVac now has one of the most successful company managers in the German pharmaceutical industry on the Board. Hartmut Retzlaff has been head of STADA AG since 1994 ...